A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease

Allergic sensitization and viral infections are risk factors for asthma development and progression. Sublingual vaccination with MV130, a whole heat-inactivated polybacterial preparation, protects against viral infections, but its impact on allergic sensitization and asthma development remains unkno...

Descripción completa

Detalles Bibliográficos
Autores: Sevilla-Ortega, Carmen, Angelina, Alba, Martín-Cruz, Leticia, Pérez-Diego, Mario, Maldonado, Angel, Lavín, Begoña, Marcos-Ramiro, Beatriz, Pérez de Llano, Luis, Gayá, Auba, Real, Francisco X., Conejero, Laura, Subiza, José Luis, Palomares, Oscar
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/72810
Acceso en línea:https://hdl.handle.net/10230/72810
http://dx.doi.org/10.1038/s41467-025-62632-x
Access Level:acceso abierto
Palabra clave:Inactivated vaccines
Mucosal immunology
Translational immunology
id ES_c25f44f3f122eb36214cefeed121b4e7
oai_identifier_str oai:recercat.cat:10230/72810
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease
title A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease
spellingShingle A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease
Sevilla-Ortega, Carmen
Inactivated vaccines
Mucosal immunology
Translational immunology
title_short A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease
title_full A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease
title_fullStr A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease
title_full_unstemmed A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease
title_sort A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease
dc.creator.none.fl_str_mv Sevilla-Ortega, Carmen
Angelina, Alba
Martín-Cruz, Leticia
Pérez-Diego, Mario
Maldonado, Angel
Lavín, Begoña
Marcos-Ramiro, Beatriz
Pérez de Llano, Luis
Gayá, Auba
Real, Francisco X.
Conejero, Laura
Subiza, José Luis
Palomares, Oscar
author Sevilla-Ortega, Carmen
author_facet Sevilla-Ortega, Carmen
Angelina, Alba
Martín-Cruz, Leticia
Pérez-Diego, Mario
Maldonado, Angel
Lavín, Begoña
Marcos-Ramiro, Beatriz
Pérez de Llano, Luis
Gayá, Auba
Real, Francisco X.
Conejero, Laura
Subiza, José Luis
Palomares, Oscar
author_role author
author2 Angelina, Alba
Martín-Cruz, Leticia
Pérez-Diego, Mario
Maldonado, Angel
Lavín, Begoña
Marcos-Ramiro, Beatriz
Pérez de Llano, Luis
Gayá, Auba
Real, Francisco X.
Conejero, Laura
Subiza, José Luis
Palomares, Oscar
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Inactivated vaccines
Mucosal immunology
Translational immunology
topic Inactivated vaccines
Mucosal immunology
Translational immunology
description Allergic sensitization and viral infections are risk factors for asthma development and progression. Sublingual vaccination with MV130, a whole heat-inactivated polybacterial preparation, protects against viral infections, but its impact on allergic sensitization and asthma development remains unknown. Here we show MV130 prevents house dust mite (HDM)-induced local type 2 immune responses and associated eosinophilic airway inflammation, conferring protection up to 9 weeks after vaccination. MV130 reduces pathophysiological and clinical asthma features in an in vivo experimental mouse model of HDM-induced allergic eosinophilic asthma, restoring normal airway functionality. MV130 impairs allergen-specific IgE sensitization and systemic type 2 inflammation endorsing type 1 and IL-10 responses. In human DCs, MV130 induces a transcriptomic and metabolic reprogramming, and restores non-pathological immune responses to allergens in healthy and asthmatic donors. Additionally, the adoptive transfer of MV130-stimulated BMDCs was sufficient to reproduce the protective features of the vaccine administration in vivo. Collectively, we show MV130 reduces allergic sensitization and eosinophilic asthma. Our findings support the exploration of mucosal interventions aimed at reducing the risk of allergen-induced asthma development.
publishDate 2025
dc.date.none.fl_str_mv 2025
2026
2026
2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/10230/72810
http://dx.doi.org/10.1038/s41467-025-62632-x
https://hdl.handle.net/10230/72810
url https://hdl.handle.net/10230/72810
http://dx.doi.org/10.1038/s41467-025-62632-x
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Nature Communications. 2025;16(1):7129
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Nature Research
publisher.none.fl_str_mv Nature Research
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869418660405182464
spelling A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway diseaseSevilla-Ortega, CarmenAngelina, AlbaMartín-Cruz, LeticiaPérez-Diego, MarioMaldonado, AngelLavín, BegoñaMarcos-Ramiro, BeatrizPérez de Llano, LuisGayá, AubaReal, Francisco X.Conejero, LauraSubiza, José LuisPalomares, OscarInactivated vaccinesMucosal immunologyTranslational immunologyAllergic sensitization and viral infections are risk factors for asthma development and progression. Sublingual vaccination with MV130, a whole heat-inactivated polybacterial preparation, protects against viral infections, but its impact on allergic sensitization and asthma development remains unknown. Here we show MV130 prevents house dust mite (HDM)-induced local type 2 immune responses and associated eosinophilic airway inflammation, conferring protection up to 9 weeks after vaccination. MV130 reduces pathophysiological and clinical asthma features in an in vivo experimental mouse model of HDM-induced allergic eosinophilic asthma, restoring normal airway functionality. MV130 impairs allergen-specific IgE sensitization and systemic type 2 inflammation endorsing type 1 and IL-10 responses. In human DCs, MV130 induces a transcriptomic and metabolic reprogramming, and restores non-pathological immune responses to allergens in healthy and asthmatic donors. Additionally, the adoptive transfer of MV130-stimulated BMDCs was sufficient to reproduce the protective features of the vaccine administration in vivo. Collectively, we show MV130 reduces allergic sensitization and eosinophilic asthma. Our findings support the exploration of mucosal interventions aimed at reducing the risk of allergen-induced asthma development.This work was supported by grant IND2019/BMD17182 to O.P. from the Industrial Doctoral Program (UCM-Inmunotek S.L) from Comunidad Autónoma de Madrid (CAM). C.S.-O. was contracted with this grant by Inmunotek SL to perform her Doctoral Thesis in UCM. O.P. laboratory is also supported by grant PID2020-114396RB-I00 from MICINN, Spain. Work in the lab of F.X.R. was supported, in part, by grant PID2021-128125OB-I00 from Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (co-funded by the ERDF-EU). CNIO is supported by Ministerio de Ciencia, Innovación y Universidades as a Centro de Excelencia Severo Ochoa SEV-2015-0510." A.G. is recipient of a predoctoral fellowship from AECC.Nature Research2026202620252026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/10230/72810http://dx.doi.org/10.1038/s41467-025-62632-xhttps://hdl.handle.net/10230/72810reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésNature Communications. 2025;16(1):7129© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/728102026-05-29T05:05:01Z
score 15,811543